

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

POSITIVE PROFIT ALERT

This announcement is published by the Company simultaneously on the Shanghai Stock Exchange pursuant to the Rules Governing the Listing of Stocks on Shanghai Stock Exchange and on The Stock Exchange of Hong Kong Limited pursuant to the disclosure obligations under Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The Board hereby announces that the Company is expecting to record an increase in the revenue and net profit attributable to shareholders of the Company for the year ended December 31, 2022 in comparison with the corresponding period in the year of 2021.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

This announcement is published by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) simultaneously on the Shanghai Stock Exchange pursuant to the Rules Governing the Listing of Stocks on Shanghai Stock Exchange and on The Stock Exchange of Hong Kong Limited pursuant to the disclosure obligations under Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The board of directors of the Company (the “**Board**”) hereby announces that the Company (together with its subsidiaries, the “**Group**”) is expecting to record an increase in the revenue and net profit attributable to shareholders of the Company for the year ended December 31, 2022 in comparison with the corresponding period in the year of 2021.

Important Notice:

1. The revenue of the Company was estimated to be approximately RMB39,354.7778 million for the year of 2022, representing a year-over-year increase of approximately 71.84% compared with RMB22,902.3851 million for the year of 2021.
2. The net profit attributable to shareholders of the Company was estimated to be approximately RMB8,813.7130 million for the year of 2022, representing a year-over-year increase of approximately 72.91% compared with RMB5,097.1553 million for the year of 2021, and the basic earnings per share was estimated to be approximately RMB3.01 for the year of 2022, representing a year-over-year increase of approximately 72.00% compared with RMB1.75 for the year of 2021.
3. The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss was estimated to be approximately RMB8,260.2897 million for the year of 2022, representing a year-over-year increase of approximately 103.27% compared with RMB4,063.6332 million for the year of 2021.
4. The adjusted non-IFRS net profit attributable to shareholders of the Company was estimated to be approximately RMB9,399.2658 million for the year of 2022, representing a year-over-year increase of approximately 83.17% compared with RMB5,131.3086 million for the year of 2021.

I. ESTIMATED RESULTS FOR THE CURRENT PERIOD

(1) Period to which the estimated results apply

January 1, 2022 to December 31, 2022.

(2) Estimated Results

1. Based on the preliminary calculation by the finance department of the Company, the revenue of the Company was estimated to be approximately RMB39,354.7778 million for the year of 2022, representing a year-over-year increase of approximately 71.84% compared with RMB22,902.3851 million for the year of 2021.
2. The net profit attributable to shareholders of the Company was estimated to be approximately RMB8,813.7130 million for the year of 2022, representing a year-over-year increase of approximately 72.91% compared with RMB5,097.1553 million for the year of 2021, and the basic earnings per share was estimated to be approximately RMB3.01 for the year of 2022, representing a year-over-year increase of approximately 72.00% compared with RMB1.75 for the year of 2021.

3. The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss was estimated to be approximately RMB8,260.2897 million for the year of 2022, representing a year-over-year increase of approximately 103.27% compared with RMB4,063.6332 million for the year of 2021.
4. The adjusted non-IFRS net profit attributable to shareholders of the Company was estimated to be approximately RMB9,399.2658 million for the year of 2022, representing a year-over-year increase of approximately 83.17% compared with RMB5,131.3086 million for the year of 2021.

(3) The estimated operating results have not been audited by a certified public accountant.

II. RESULTS OF THE CORRESPONDING PERIOD IN THE YEAR OF 2021

- (1) Revenue of the Company: RMB22,902.3851 million. Net profit attributable to shareholders of the Company: RMB5,097.1553 million. Net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss: RMB4,063.6332 million. Adjusted non-IFRS net profit attributable to shareholders of the Company: RMB5,131.3086 million.
- (2) Basic earnings per share: RMB1.75.

III. MAIN REASONS FOR THE ESTIMATED GROWTH IN RESULTS FOR THE CURRENT PERIOD

(1) Impact of the principal business

1. The revenue of the Company for the year of 2022 was estimated to be a record high growth, representing a year-over-year increase of approximately 71.84%. The unique Contract Research Development and Manufacturing Organization (CRDMO) and Contract Testing Development and Manufacturing Organization (CTDMO) business models of the Company continued to drive rapid growth. Despite the ongoing resurgence of the COVID-19 pandemic in various regions around the world in 2022, the Company swiftly formulated and effectively implemented its business continuity plan, fully capitalizing on its global capacity, multiple operational locations and comprehensive coverage across industry supply chains, which ensured the achievement of its overall performance targets.

2. The adjusted non-IFRS net profit attributable to shareholders of the Company for the year of 2022 was estimated to record a year-over-year increase of approximately 83.17%, outpacing revenue growth over the same period, which was as a result of the Company continuously raising its production capacity utilization rate and further demonstrating its economy of scale through the continuous optimization of operating efficiency.

(2) Impact of non-recurring profit or loss

The impact of the non-recurring profit or loss items on profit for the year of 2022 primarily includes: the fair value changes and investment gains and losses of the capital investment portfolios were estimated to be a net gain of approximately RMB183.2653 million for the year of 2022, representing a year-over-year decrease of approximately RMB1,479.6658 million compared with a net gain of RMB1,662.9311 million for the year of 2021; however, the changes in fair value and investment gains and losses of the derivative financial instruments for the year of 2022 were estimated to be a net gain of approximately RMB109.0057 million, representing a turn-around of approximately RMB1,104.6475 million as compared to the net loss of RMB995.6418 million for the year of 2021.

IV. RISK WARNING

There are no significant uncertainties pertaining to the Company which may affect the accuracy of the estimated results.

V. OTHER INFORMATION

The Board would like to remind the investors that the above estimated results of the Company for the year ended December 31, 2022 were prepared based on preliminary accounting information only. Please refer to the announcement of the audited 2022 annual results of the Company to be published subsequently for the finalized financial figures. Investors are advised to pay attention to the investment risks.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, January 30, 2023

As at the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Dr. Minzhang Chen, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou, Mr. Xiaotong Zhang and Mr. Dai Feng as independent non-executive Directors.

* *For identification purposes only*